Trial data sounds death knell for Iressa
December 21, 2004Sales and Marketing
AstraZeneca has effectively given up on its cancer drug Iressa, admitting that data from a new large scale trial shows …
FDA recommends alternatives following Celebrex scare
December 21, 2004Sales and Marketing
A new study linking Celebrex to the same increased risk of heart attacks and strokes as recently withdrawn Vioxx has …
AstraZeneca looks to Iressa successor after setback
December 16, 2004Research and Development
AstraZeneca says it is optimistic about two of its most advanced cancer pipeline drugs, which it hopes will offset a …
Restructured Takeda to go it alone on hypertension drug
December 16, 2004Takeda is to assume full control of marketing hypertension drug candesartan in the UK from January, ending a seven-year collaboration …
Payments by Results could bankrupt hospitals, say doctors’ leaders
December 16, 2004NHS hospitals that fail to attract patients could become bankrupt under the Payments by Results system, doctors' leaders have warned.Due …
Academics raise alarm over trial costs
December 15, 2004Leading UK academic researchers say extra costs and bureaucracy from new European laws are killing off their work, and have …
Taking the plunge
December 10, 2004When prompted to do some forward thinking, I often start by looking back. In 1999 I was an evangelist for …
Bextra to carry new safety warnings in US
December 10, 2004Pfizer’s painkiller Bextra will have to carry stronger warnings in the US about increased risk of potentially fatal skin reactions …
inChord buys Junction 11 advertising agency
December 10, 2004Medical Communications Junction 11, comms, inVentiv Health
Global healthcare communications company inChord Communications has expanded its European base by buying the UK Junction 11 agency.inChord has its …
Chiron manufacturing ban extended
December 10, 2004Chiron is facing a further three-month ban on vaccine production at its Liverpool factory, after problems were first detected by …
Efexor singled out in antidepressant safety review
December 7, 2004A long-awaited investigation into the safety of modern antidepressants has concluded that the SSRI class of drugs is safe, but …
Have you perfected the work/life balance?
December 3, 2004Perfecting the balance between work and the rest of life is increasingly a concern for employees and employers – based …
Life-saving licence to boost Diovan
December 2, 2004Sales of Novartis' hypertension treatment Diovan look set to increase following the granting of a new European Union licence for …
Cegedim service provides ‘integrated picture’ of markets
December 1, 2004Pharmaceutical marketing data specialist Cegedim has launched a suite of new services to help pharma companies better understand their customers …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
